Cell and Gene Therapy: European Heatmap 2019

Cell and Gene Therapy: European Heatmap 2019

Back by popular demand, the 2019 industry heatmap provides a high level overview of the latest developments in the European novel therapy manufacturing space across The United Kingdom, Belgium, Greece and Switzerland, among others

With the 2018 commercialisation of prominent Autologous therapies such as KITEs Yskarta and Novartis’ Kymriah in the global market, more and more companies are beginning to move towards commercially based products. Yet despite these unquestionable industry growths, challenging issues can hinder – and even halt – groundbreaking progress in its tracks. There are still no established routes to market and with continuous changes in regulatory requirements across different global markets achieving any form of standardisation is difficult.

Download this free resource to gain valuable insights on some of the biggest challenges:

  • globalising production and commercialisation
  • scalability
  • cost efficiency
  • regulatory pathways
  • supply and logistics


Please note: That all fields marked with an asterisk (*) are required.